![[F] Why France is making eight new vaccines mandatory](/uploads/r/null/1/b/5/1b5f028151073a811ab7ac2e22c443c507a8b163a30a6d332f5bddb24bba8d3d/4dd2d185-cd5a-4516-98ea-90f85e3de0c0-_F__wardwhyfranceismaking8newvaccinesmandatory_142.jpg)
Paper on Why France is making eight new vaccines mandatory
![[F] WHO Ending Tuberculosis in Children.pdf](/uploads/r/null/7/e/d/7eddd5b37e7d5f92c2f4303672812b599f8002feb40225789d972c0194fc9f04/024f940c-177b-42cd-811a-024b1de1018c-_F__WHO_Ending_Tuberculosis_in_Children_142.jpg)
![[F] Update with the development of Ebola vaccines and implications of emerging evidence to inform future policy recommendations](/uploads/r/null/3/5/9/3597bba84176f2241e8a930dcddb2c893eeb9fae875d9f6cfb1dafd303d9e3b7/2fca850a-2671-400d-99ce-aeecf4b4ceb5-_F__2_Ebola_SAGE2018Oct_BgDoc_20180919_142.jpg)
![[F] UNHCR Rwanda Country Response Plan](/uploads/r/null/0/5/c/05c709cefc9670826925dc405797b0060a4772aed5ac7dc02aad1ef1c2bd4cfd/9fdd9dc8-52b4-4bd0-a950-c3080f40bf0e-_F__Rwanda_Country_Refugee_Response_Plan_2020-2021_-_March_2020_142.jpg)
UNHCR Rwanda Country Response Plan January 2020 – December 2021
UNCHR![[F] UNAIDS (2020). Prevailing Against Pandemics by Putting People At The Centre: World AIDS Day Report 2020](/uploads/r/null/0/d/7/0d771874537a8e56b2bd6932dc60d3135560cf62cb742224abc67d4474b06d1d/ce32940d-efe4-4fe7-9a6b-617874d92b3f-_F__prevailing-against-pandemics_en_142.jpg)
![[F] The Global Fund Result Reports 2020.pdf](/uploads/r/null/6/2/5/62512e37e24dc146d60041bbf6df2074c8d2a09dc15f368068d5eaf664ea27dd/b7f4064c-33b6-4c5a-9db8-1919995c4ef5-_F__The_Global_Fund_Result_Reports_2020_142.jpg)
![[F] The Global Fund Result Reports 2020](/uploads/r/null/6/2/5/62512e37e24dc146d60041bbf6df2074c8d2a09dc15f368068d5eaf664ea27dd/f96ede62-b022-4378-96ef-b4a2a86d7a6c-_F__corporate_2020resultsreport_report_en_142.jpg)
![[F] SweetGen: abiotic wastewater fuel cell](/uploads/r/null/4/5/0/45038773f0a32fbcabbcda6a181f051d4acb133408176f20c013fe64c391dab9/992543b7-003f-4835-9016-19218967da2e-_F__screencapture-rsc-org-competitions-emerging-technologies-case-studies-sweetgen-2021-03-02-09_30_35_142.jpg)
Feature on SweetGen
![[F] Solvent effects on electronic excitations of an organic chromophore](/uploads/r/null/e/1/0/e1000e5caf64648ce084425c6586bf2482fa2a8abfd2f2635dee62364ac7aacf/b0d4c0f7-0fb2-42d7-98b4-6fec6ffeb610-_F__Zuehlsdorff_2016_142.jpg)
Paper in partnership with DS BIOVIA
![[F] Quantum technologies: Government Response to the Committee’s Twelfth Report](/uploads/r/null/f/d/5/fd52fad7ef6b41a9e1420a748d1ed17980a9e7c3b88be74fa1d7808be8dd43dc/91e59817-7b64-471c-982b-292dc26f2cbc-_F__QT_12th_Report_142.jpg)
Government response to the Science and technology committee's report on Quantum
Parliament![[F] Quality Accounts of Oxford University Hospital for 2018/19](/uploads/r/null/2/4/d/24d467b84d18c52300e8120810bf31f9ae1d99504b428de6d5d8f7ab937d363b/5f12306e-9507-4c59-a40a-975090b86010-_Fb__quality-report-2019_142.jpg)
![[F] Quality Accounts of Oxford University Hospital for 2017/8](/uploads/r/null/8/0/f/80f192b4ef4bdd9c26b1aeae3a0857092d58b28821b007595c1b36edc2bc44ae/14e5a397-35b3-4711-b78f-b678ef2963c6-_Fa__quality-account-2018_142.jpg)
![[F] Pre-Kymeta Series Part 2: The Invisibility Cloak](/uploads/r/null/b/2/b/b2b5ff419d61aaea75490c8c16e8889e4ea5f912b709757122af9f15c5979d85/0b3681af-39d5-4b92-9733-2e0b4250e051-_F__kymetacorp-blog-pre-kymeta-part-2-2020-04-08-14_06_43_142.jpg)
A article detailing the Jon Pendry's research and it importance to Kymeta
Kymeta![[F] Phase 1 UK Plant Health Risk Register –Summary Guide](/uploads/r/null/9/5/e/95ecd7abd5b277c06be47e9133f8bd6426052ffa451fffa87a17ac0f72279e60/3a423ebb-1608-4b68-bd69-574e6cb62d0f-_F__DEFRA_Summary-of-Guidance-for-phase-1-Public-Ver2_142.jpg)
Final report of DEFRA's Tree Health and Plant Biosecurity Expert Taskforce
Defra![[F] Paper showing results from the Phase 1 Trials](/uploads/r/null/a/e/d/aed3b77b6beb073170033c1eb93b61f3a3ad97d2a3f986690ba90d27b95857f1/f3abbe5b-cfe1-4b52-98bf-04f9ce1ab0b0-_F__Lockwood_2006_142.jpg)
Results from the Phase 1 Trials - Feasibility and safety of delivering xenon to patients undergoing coronary artery bypass graft surgery while on cardiopulmonary bypass: phase I study
![[F] Nightstar timeline.pdf](/uploads/r/null/8/e/3/8e3cf0b67ccffd93e1a4c528df4aed99e23acf77965dbb81de3f986eaa35c42f/37037075-8245-4641-bde4-ab11ec30603a-_F__Nightstar_timeline_142.jpg)
![[F] New cancer drug class unveiled at Imperial](/uploads/r/null/7/1/7/717cdab622fc778c12d5fd88d8da5a686b35113ca1cf863f0f5e8dbb254a2f61/bc9f34a9-cb1a-41f3-9c1a-49a79e6c0a22-_F_-b-s-h-org-uk_2020-12-01-08_47_02_142.jpg)
News story on new cancer drug class unveiled at Imperial
British Society for Haematology![[F] National Advisory Committee on Immunization (NACI) Canada. LAIV Use in Egg Allergic Individuals Advisory Committee Statement.pdf](/uploads/r/null/0/8/6/086ae511e33f399158b3947b2e2c874707ad2bd4193184eb5c2bd9a0dea4576f/d893f21b-38e3-4694-8e4c-1dcace0c3a11-_F__National_Advisory_Committee_on_Immunization__NACI__Canada._LAIV_Use_in_Egg_Allergic_Individuals_Advisory_Committee_Statement_142.jpg)
![[F] National Action Plan (NAP)](/uploads/r/null/e/5/f/e5f060683182c6af57575af6f819855958e1c35cc9f4056ae5cadc3fea7dfe1f/4afba35f-f598-4d60-b378-2d35d1dedb59-_F__NAP_142.jpg)
The National Action Plan (NAP)
![[F] Minutes of the seventy-third SAGE meeting on Covid-19. 17 Dec 2020 reference to data from REACT-1 in points 32 and 33..pdf](/uploads/r/null/6/a/e/6ae9361e02d7ad8fcc2285ed9819943a6dedb6705d1adc889cdf3241493487e2/dd364c80-8c9a-4c8c-88a7-4684e5eb9266-_F__Minutes_of_the_seventy-third_SAGE_meeting_on_Covid-19._17_Dec_2020_reference_to_data_from_REACT-1_in_points_32_and_33._142.jpg)